Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zai Lab Limited

< Previous 1 2 3 Next >
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
Tickers NVCR ZLAB
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in June Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
Tickers KRTX ZLAB
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in February Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
Tickers NVCR ZLAB
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in January Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.